Alzheimer's disease symptoms and progression result from a chronic neuro-inflammation in the brain that destroys synapses, the means through which neurons communicate.  MindImmune has determined that the cells responsible for the attack on synapses are a type of innate immune cell that is recruited into the brain from the blood in response to Alzheimer's disease pathology.  MindImmune has discovered a way to block this immune cell recruitment and is developing this finding into a new therapeutic approach to Alzheimer's disease.  The work funded by ADDF supports the development of a method to measure immune cell recruitment in Alzheimer's patients.  This may serve as a new diagnostic for the disease and as an aid to the development of MindImmune's new therapeutic approach to nip Alzheimer's disease in the blood'.